Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Improved Outcomes for Pediatric B-ALL but Inferior Survival for T-ALL Using the Same Treatment Protocol: Results of Consecutive Malaysia-Singapore 2003 and 2010 Childhood ALL Trials

Shawn H.R. Lee, Bernice Oh, Prasad Iyer, Yiong Huat Chan, Kean Hui Chiew, Shirley Kow Yin Kham, Michaela Su-Fern Seng, Joyce CM Lam, Lee Lee Chan, Thuan Chong Quah, Hai Peng Lin, Ah Moy Tan, Hany Ariffin, Allen Eng Juh Yeoh

Blood (2024) 144 (Supplement 1): 4192.

https://doi.org/10.1182/blood-2024-193344

Published: 2024

Journal Articles

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

John B Porter, MD, Mohsen Elalfy, MD, Ali T Taher, MD, Lee Lee Chan, MD, Szu-Hee Lee, MD, Pranee Sutcharitchan, MD, Yesim Aydinok, MD, Subhashish Chakravarty, PhD, Ali El-Ali, MD, Amal El-Beshlawy, MD/Professor

Blood (2014) 124 (21): 52.

https://doi.org/10.1182/blood.V124.21.52.52

Published: 2014

Journal Articles

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

Amal El-Beshlawy, MD, Mohsen Elalfy, MD, Lee Lee Chan, MD, Yongrong Lai, MD, Kai-Hsin Lin, MD, Yesim Aydinok, MD, Renzo Galanello, MD, Ali El-Ali, MD, Nicolas Martin, MS, M Domenica Cappellini, MD

Blood (2012) 120 (21): 1028.

https://doi.org/10.1182/blood.V120.21.1028.1028

Published: 2012

Journal Articles

Serum Ferritin, Labile Plasma Iron and Transferrin Saturation: Comparison Between Underlying Anemias with Transfusional Iron Overload Before and After Treatment with Deferasirox.

John B Porter, MD, Mohsen Elalfy, MD, Vip Viprakasit, MD, DPhil, Stephane Giraudier, MD, Lee Lee Chan, MD, Yongrong Lai, MD, Ali El-Ali, MD, Nicolas Martin, MS, M Domenica Cappellini, MD

Blood (2012) 120 (21): 2126.

https://doi.org/10.1182/blood.V120.21.2126.2126

Published: 2012

Journal Articles

Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years

Dudley Pennell, MD, John B. Porter, MD, Maria Domenica Cappellini, MD, Lee Lee Chan, MD, Amal El-Beshlawy, MD, Yesim Aydinok, MD, Hishamshah Ibrahim, MD, Chi-Kong Li, MD, Vip Viprakasit, MD, DPhil, Mohsen Saleh Elalfy, MD, Antonis Kattamis, MD, Gillian Smith, MSc, Dany Habr, MD, Gabor Domokos, PhD, Bernard Roubert, PhD, Ali Taher, MD

Blood (2010) 116 (21): 4276.

https://doi.org/10.1182/blood.V116.21.4276.4276

Published: 2010

Journal Articles

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Amal El-Beshlawy, Lee Lee Chan, Yesim Aydinok, Mohsen Saleh Elalfy, Pranee Sutcharitchan, Chi-Kong Li, Hishamshah Ibrahim, Vip Viprakasit, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher

Blood (2010) 115 (12): 2364–2371.

https://doi.org/10.1182/blood-2009-04-217455

Published: 2010

Journal Articles

Improvement in Right Ventricular Function Following 1 Year of Deferasirox Therapy in Patients with β-Thalassemia.

Gillian Smith, Dudley J. Pennell, John B. Porter, M. Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Lee, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Dany Habr, Gabor Domokos, Abdel Hmissi, Ali Taher

Blood (2009) 114 (22): 5106.

https://doi.org/10.1182/blood.V114.22.5106.5106

Published: 2009

Journal Articles

History of Hepatitis B or C Does Not Affect Safety and Efficacy of Deferasirox (Exjade®) in Thalassemia Major Patients: Sub-Analysis of the EPIC Trial.

M. Domenica Cappellini, Mohsen Saleh Elalfy, Amal El-Beshlawy, Antonis Kattamis, Lee Lee Chan, ChunFu Li, Kai-Hsin Lin, Giovanni Quarta, Pranee Sutcharitchan, Ali Taher, Dany Habr, Gabor Domokos, Bernard Roubert, John B. Porter

Blood (2009) 114 (22): 5107.

https://doi.org/10.1182/blood.V114.22.5107.5107

Published: 2009

Journal Articles

Deferasirox (Exjade®) ≥30 Mg/Kg/Day Is Effective in Reducing Iron Burden in Thalassemia Major Patients Previously Chelated with Monotherapy or Combination Therapy.

Ali Taher, Mohsen Saleh Elalfy, Amal El-Beshlawy, Dunhua Zhou, Lee Lee Chan, Chi-Kong Li, Kai-Hsin Lin, John B. Porter, Pranee Sutcharitcharan, Dany Habr, Gabor Domokos, Bernard Roubert, M. Domenica Cappellini

Blood (2009) 114 (22): 4058.

https://doi.org/10.1182/blood.V114.22.4058.4058

Published: 2009

Journal Articles

Efficacy and Safety of Deferasirox (Exjade®) in β-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.

Dudley J. Pennell, John B. Porter, M. Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher

Blood (2009) 114 (22): 4062.

https://doi.org/10.1182/blood.V114.22.4062.4062

Published: 2009

Journal Articles

Analysis of 120 Pediatric Patients with Non-Malignant Disorders Transplanted Using Unrelated Plasma Depleted Cord Blood and the Role of Post-Thaw Wash

Joseph Rosenthal, MD, MS, Tang-Her Jaing, MD, Lee Lee Chan, MD, Gretchen Eames, MD, Michael L. Graham, MD, Ah Moy Tan, MD, Hai Peng Lin, MD, Auayporn P. Nademanee, MD, Chatchada Karanes, MD, Brian Wang, MS, Tina Wu, Tiffany Chow, Patrick Tan, MD, David Gjertson, PhD, Lawrence Petz, MD, Stephen J. Forman, MD, Robert Chow, MD

Blood (2008) 112 (11): 4406.

https://doi.org/10.1182/blood.V112.11.4406.4406

Published: 2008

Journal Articles

The Tolerability, Safety and Efficacy of a New Oral Solution of Deferiprone in Children with Transfusional Iron Overload

Mohsen Saleh El-Alfy, M.D., Teny Tjitra Sari, M.D., Lee Lee Chan, Fernando Tricta, MD, Amal El-Beshlawy

Blood (2008) 112 (11): 5373.

https://doi.org/10.1182/blood.V112.11.5373.5373

Published: 2008

Journal Articles

Post-That Washing Prior to Transplantation of Umbilical Cord Blood (UCB) That Were Depleted of Plasma but Not of Red Blood Cells.

Robert Chow, MD, Patrick Tan, M.D., Tang-Her Jaing, M.D., Joseph Rosenthal, M.D., Auayporn Nademanee, M.D., Chatchada Karanes, M.D., Michael Graham, M.D., Gretchen Eames, M.D., Lee Lee Chan, M.D., Brian Wang, M.S., Tiffany Chow, Tina Wu, Ah Moy Tan, M.D., Poh-Lin Tan, M.D., Hai-Peng Lin, M.D., David Gjertson, PhD, Lawrence Petz, M.D.

Blood (2006) 108 (11): 5229.

https://doi.org/10.1182/blood.V108.11.5229.5229

Published: 2006

Journal Articles

Hematopoietic Stem Cell Transplantation (HSCT) Using Plasma Depleted Umbilical Cord Blood (UCB) That Were Not Red Cell Depleted.

Blood (2006) 108 (11): 5231.

https://doi.org/10.1182/blood.V108.11.5231.5231

Published: 2006

Journal Articles

Hematopoietic Stem Cell Transplantation (HSCT) for Malignancies Using Plasma Depleted Umbilical Cord Blood (UCB) That Were Not Red Blood Cell Depleted.

Lawrence Petz, MD, Auayporn Nademanee, M.D., Joseph Rosenthal, M.D., Michael Graham, M.D., Gretchen Eames, M.D., Chatchada Karanes, M.D., Lee Lee Chan, M.D., Ah Moy Tan, M.D., Poh-Lin Tan, M.D., Brian Wang, M.S., Peggy Tseng, Tiffany Chow, Tina Wu, Tang-Her Jaing, M.D., David Gjertson, PhD, Patrick Tan, M.D., Robert Chow, MD

Blood (2006) 108 (11): 5418.

https://doi.org/10.1182/blood.V108.11.5418.5418

Published: 2006

Journal Articles

Comparison of Cord Blood Transplant Outcome between U.S. Versus Non-U.S. Transplant Centers for Cord Blood from a Single Source.

Brian Wang, MS, Peggy Tseng, Tina Wu, Joseph Rosenthal, M.D., Tang-Her Jaing, M.D., Lee Lee Chan, M.D., Ah Moy Tan, M.D., Poh-Lin Tan, M.D., Hai-Peng Lin, M.D., Allen Lin, M.T., Steven Yang, M.T., Tiffany Chow, David Gjertson, Ph.D., Lawrence Petz, M.D., Patrick Tan, M.D., Robert Chow, M.D.

Blood (2006) 108 (11): 5419.

https://doi.org/10.1182/blood.V108.11.5419.5419

Published: 2006

Journal Articles

Hematopoietic Stem Cell Transplantation (HSCT) for Benign Indications Using Plasma Depleted Umbilical Cord Blood Units (UCB) That Were Not Depleted of Red Blood Cells.

Joseph Rosenthal, MD, Tang-Her Jaing, M.D., Auayporn Nademanee, M.D., Chatchada Karanes, M.D., Michael Graham, M.D., Lee Lee Chan, M.D., Gretchen Eames, M.D., Ah Moy Tan, M.D., Poh-Lin Tan, M.D., Brian Wang, M.S., Peggy Tseng, Tiffany Chow, Tina Wu, Hai-Peng Lin, M.D., David Gjertson, PhD, Lawrence Petz, M.D., Patrick Tan, M.D., Robert Chow, M.D.

Blood (2006) 108 (11): 3151.

https://doi.org/10.1182/blood.V108.11.3151.3151

Published: 2006

NARROW

Improved Outcomes for Pediatric B-ALL but Inferior Survival for T-ALL Using the Same Treatment Protocol: Results of Consecutive Malaysia-Singapore 2003 and 2010 Childhood ALL Trials

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

Serum Ferritin, Labile Plasma Iron and Transferrin Saturation: Comparison Between Underlying Anemias with Transfusional Iron Overload Before and After Treatment with Deferasirox.

Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

Improvement in Right Ventricular Function Following 1 Year of Deferasirox Therapy in Patients with β-Thalassemia.

History of Hepatitis B or C Does Not Affect Safety and Efficacy of Deferasirox (Exjade®) in Thalassemia Major Patients: Sub-Analysis of the EPIC Trial.

Deferasirox (Exjade®) ≥30 Mg/Kg/Day Is Effective in Reducing Iron Burden in Thalassemia Major Patients Previously Chelated with Monotherapy or Combination Therapy.

Efficacy and Safety of Deferasirox (Exjade®) in β-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.

Analysis of 120 Pediatric Patients with Non-Malignant Disorders Transplanted Using Unrelated Plasma Depleted Cord Blood and the Role of Post-Thaw Wash

The Tolerability, Safety and Efficacy of a New Oral Solution of Deferiprone in Children with Transfusional Iron Overload

Post-That Washing Prior to Transplantation of Umbilical Cord Blood (UCB) That Were Depleted of Plasma but Not of Red Blood Cells.

Hematopoietic Stem Cell Transplantation (HSCT) Using Plasma Depleted Umbilical Cord Blood (UCB) That Were Not Red Cell Depleted.

Hematopoietic Stem Cell Transplantation (HSCT) for Malignancies Using Plasma Depleted Umbilical Cord Blood (UCB) That Were Not Red Blood Cell Depleted.

Comparison of Cord Blood Transplant Outcome between U.S. Versus Non-U.S. Transplant Centers for Cord Blood from a Single Source.

Hematopoietic Stem Cell Transplantation (HSCT) for Benign Indications Using Plasma Depleted Umbilical Cord Blood Units (UCB) That Were Not Depleted of Red Blood Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only